ADC2GBM (Development of brain-permeable masked nanobody-drug conjugates to eliminate glioma stem cells)
Funds Source:
European Union
Period:
01/05/2022 to 30/04/2024
Project typology:
Individual project
Project status:
ACTIVE
Funding Entity:
Comisión Europea (CE)
Funding:
165,312 €
Innovative formulation to treat glioma using brain-permeable masked nanobody-drug conjugates.
The main objective of this proposal is to develop a masked nanobody-drug conjugate with the capacity to overcome the BBB and to be activated only in the tumour to selectively target GSCs.
The concept of GSC-targeting with activatable ADC may change the current paradigm for the treatment of brain tumours. Furthermore, our workflow may be applied to dramatically enhance the efficacy of other biotherapeutics with on-target off-site dose-limiting effects.
Research groups
GEMAT – Materials Engineering
The GEMAT group (Materials Engineering Group) conducts its activity in three main areas: the development of new functional materials, surface engineering and biomaterials.
ChemSynBio – Chemical & Synthetic Biology for Biotherapies
In the ChemSynBio group (Chemical & Synthetic Biology for Biotherapies) we combine the power of chemical and synthetic biology to create protein-based precision therapeutics and biomedical tools. Our main goals are to treat brain tumors and other brain diseases, and to understand and improve drug transport across the blood-brain barrier.